scholarly journals Expanding One-Pot Cell-Free Protein Synthesis and Immobilization for On-Demand Manufacturing of Biomaterials

2018 ◽  
Vol 7 (3) ◽  
pp. 875-884 ◽  
Author(s):  
Ana I. Benítez-Mateos ◽  
Irantzu Llarena ◽  
Ana Sánchez-Iglesias ◽  
Fernando López-Gallego
2018 ◽  
Vol 14 (3) ◽  
pp. 1800271 ◽  
Author(s):  
Kristen M. Wilding ◽  
John P. Hunt ◽  
Joshua W. Wilkerson ◽  
Parker J. Funk ◽  
Rebecca L. Swensen ◽  
...  

2019 ◽  
Vol 26 (12) ◽  
pp. 1743-1754.e9 ◽  
Author(s):  
Benjamin J. Des Soye ◽  
Vincent R. Gerbasi ◽  
Paul M. Thomas ◽  
Neil L. Kelleher ◽  
Michael C. Jewett

2020 ◽  
Vol 5 (2) ◽  
pp. 270-277 ◽  
Author(s):  
Caijin Zhou ◽  
Xiaomei Lin ◽  
Yuan Lu ◽  
Jisong Zhang

A flexible on-demand cell-free protein synthesis platform using a tube-in-tube reactor is established for continuous synthesis of different protein drugs.


2021 ◽  
Author(s):  
Alicia Aquino ◽  
Zach Manzer ◽  
Susan Daniel ◽  
Matthew P DeLisa

In recent years, cell-free synthetic glycobiology technologies have emerged that enable production and remodeling of glycoproteins outside the confines of the cell. However, many of these systems combine multiple synthesis steps into one pot where there can be competing reactions and side products that ultimately lead to low yield of the desired product. In this work, we describe a microfluidic platform that integrates cell-free protein synthesis, glycosylation, and purification of a model glycoprotein in separate compartments where each step can be individually optimized. Microfluidics offer advantages such as reaction compartmentalization, tunable residence time, the ability to tether enzymes for reuse, and the potential for continuous manufacturing. Moreover, it affords an opportunity for spatiotemporal control of glycosylation reactions that is difficult to achieve with existing cell-based and cell-free glycosylation systems. In this work, we demonstrate a flow-based glycoprotein synthesis system that promotes enhanced cell-free protein synthesis, efficient protein glycosylation with an immobilized oligosaccharyltransferase, and enrichment of the protein product from cell-free lysate. Overall, this work represents a first-in-kind glycosylation-on-a-chip prototype that could find use as a laboratory tool for mechanistic dissection of the protein glycosylation process as well as a biomanufacturing platform for small batch, decentralized glycoprotein production.


2018 ◽  
Vol 12 (5) ◽  
pp. 054102 ◽  
Author(s):  
Xiao Xiao ◽  
Yuan Zhou ◽  
Yuqiong Sun ◽  
Qing Wang ◽  
Jianbo Liu ◽  
...  

2020 ◽  
Vol 117 (12) ◽  
pp. 4001-4008
Author(s):  
Wan‐Qiu Liu ◽  
Changzhu Wu ◽  
Michael C. Jewett ◽  
Jian Li

2019 ◽  
Vol 2 (2) ◽  
pp. 52 ◽  
Author(s):  
Seung-Ook Yang ◽  
Gregory H. Nielsen ◽  
Kristen M. Wilding ◽  
Merideth A. Cooper ◽  
David W. Wood ◽  
...  

Stroke is the leading cause of death with over 5 million deaths worldwide each year. About 80% of strokes are ischemic strokes caused by blood clots. Tissue plasminogen activator (tPa) is the only FDA-approved drug to treat ischemic stroke with a wholesale price over $6000. tPa is now off patent although no biosimilar has been developed. The production of tPa is complicated by the 17 disulfide bonds that exist in correctly folded tPA. Here, we present an Escherichia coli-based cell-free protein synthesis platform for tPa expression and report conditions which resulted in the production of active tPa. While the activity is below that of commercially available tPa, this work demonstrates the potential of cell-free expression systems toward the production of future biosimilars. The E. coli-based cell-free system is increasingly becoming an attractive platform for low-cost biosimilar production due to recent developments which enable production from shelf-stable lyophilized reagents, the removal of endotoxins from the reagents to prevent the risk of endotoxic shock, and rapid on-demand production in hours.


2019 ◽  
Vol 53 ◽  
pp. 73-80 ◽  
Author(s):  
Kristen M. Wilding ◽  
Emily Long Zhao ◽  
Conner C. Earl ◽  
Bradley C. Bundy

2021 ◽  
Vol 8 ◽  
Author(s):  
Alicia K. Aquino ◽  
Zachary A. Manzer ◽  
Susan Daniel ◽  
Matthew P. DeLisa

In recent years, cell-free synthetic glycobiology technologies have emerged that enable production and remodeling of glycoproteins outside the confines of the cell. However, many of these systems combine multiple synthesis steps into one pot where there can be competing reactions and side products that ultimately lead to low yield of the desired product. In this work, we describe a microfluidic platform that integrates cell-free protein synthesis, glycosylation, and purification of a model glycoprotein in separate compartments where each step can be individually optimized. Microfluidics offer advantages such as reaction compartmentalization, tunable residence time, the ability to tether enzymes for reuse, and the potential for continuous manufacturing. Moreover, it affords an opportunity for spatiotemporal control of glycosylation reactions that is difficult to achieve with existing cell-based and cell-free glycosylation systems. In this work, we demonstrate a flow-based glycoprotein synthesis system that promotes enhanced cell-free protein synthesis, efficient protein glycosylation with an immobilized oligosaccharyltransferase, and enrichment of the protein product from cell-free lysate. Overall, this work represents a first-in-kind glycosylation-on-a-chip prototype that could find use as a laboratory tool for mechanistic dissection of the protein glycosylation process as well as a biomanufacturing platform for small batch, decentralized glycoprotein production.


Sign in / Sign up

Export Citation Format

Share Document